Global LAMEA Oncology/Anti-cancer drugs Market 2014 To 2021 - Industry Trends, Market Size, Segments, Growth Prospects: Acute Market Reports

Oncology/Anti-cancer drugs are used for treating various cancer types for improving and prolonging a patients survival time. Biological drugs, based on monoclonal antibodies (mAbs) would emerge as a preferred option for treating various cancer types, especially blood cancer (leukaemia).

The rising incidence and prevalence of various cancer types, new cancer treatments and growing importance of biological and targeted drug therapies, are driving the market growth of LAMEA oncology/anti-cancer drugs. In addition, increasing demand of anti-cancer drugs for the treatment of ageing population, rising government funds and improved treatment results, are major factors boosting the market growth.

Browse Full Report here: http://www.acutemarketreports.com/report/lamea-oncology-anti-cancer-drugs-market

However, the high cost involved in new drug development, coupled with threat of failure and adverse effects associated with anti-cancer drugs therapies, would restrain the growth of the LAMEA market. Moreover, accessibility of anti-cancer drugs incurred by high cost, is a major challenge that is expected to further impede the performance of anti-cancer drugs in LAMEA region. Nevertheless, commercialization of advanced therapeutics, such as targeted therapies and immunotherapies (biologic therapies) would reduce the negative influence of restraints and fuel the market growth.

The LAMEA oncology drugs market is segmented into therapeutic modalities, cancer types and countries. Therapeutic modalities segment is further categorized into chemotherapy, targeted therapy, immunotherapy (biologic therapy), hormonal therapy and others.

The LAMEA oncology drugs market is expected to reach $17,072.2 million by 2021. Patent expiration of key anti-cancer drugs such as Herceptin (Patent Expiration: EU-2014; US-2019), Erbitux (Patent Expiration: EU-2014; US-2016), Rituxan (Patent Expiration: EU-2013; US-2018) and Avastin (Patent Expiration: EU-2018; US-2019), is expected to boost the growth of cancer biosimilars market by 2021. Further, the biological therapy is the fastest growing segment at a CAGR of 12.2%, throughout the analysis period, on account of high efficacy and target specific action. Moreover, blood cancer drugs market was the largest revenue generating application segment in 2015, owing to the high cost of drugs (immunotherapies), used for the treatment of blood cancer.

Browse All Reports of This Category @ http://www.acutemarketreports.com/category/pharmaceutical-market

Table of Content:

Chapter: 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

Chapter: 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Development of novel immuno-oncology drug products
3.3 Key findings
3.3.1 Top impacting factors
3.3.2 Top investment pockets
3.3.3 Top winning strategies
3.4 Government regulations
3.4.1 Regulations in Middle East
3.5 Reimbursement scenario
3.5.1 Reimbursement in Middle East
3.6 Drivers
3.6.1 Rising incidence and prevalence of various cancer types
3.6.2 Growing importance of biological and targeted drug therapies
3.6.3 Increasing funding and aid from public and private sector
3.7 Restraints
3.7.1 High cost of drug development and threat of failure
3.7.2 Adverse effects of cancer drug therapy
3.8 Opportunities
3.8.1 Advancement of anti-cancer drugs research
3.8.2 Healthcare and medical awareness

Chapter: 4 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES,2014-2021
4.1 Chemotherapy
4.1.1 Market size and forecast
4.2 Targeted therapy
4.2.1 Market size and forecast
4.3 Immunotherapy (biologics therapy)
4.3.1 Market size and forecast
4.4 Hormonal therapy
4.4.1 Market size and forecast
4.5 Others
4.5.1 Market size and forecast

Chapter: 5 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY CANCER TYPES,2014-2021
5.1 Blood cancer
5.1.1 Market size and forecast
5.2 Breast cancer
5.2.1 Market size and forecast
5.3 Gastrointestinal cancer
5.3.1 Market size and forecast
5.4 Prostate cancer
5.4.1 Market size and forecast
5.5 Respiratory/lung cancer
5.5.1 Market size and forecast
5.6 Skin cancer
5.6.1 Market size and forecast
5.7 Other cancers
5.7.1 Trends in treatment of other cancer types
5.7.2 Market size and forecast

Our Blogs: –

http://www.qyresearchreports.net/

http://www.deepresearchreport.com/

http://www.profresearchreport.com/

For Technology News: http://www.mobilecomputingtoday.co.uk/

About – Acute Market Reports:

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.

Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.

Contact Us:

Chris Paul

ACUTE MARKET REPORTS

Office No 101, 1st Floor ,

Aditi Mall, Baner,

Pune, MH, 411045

India

Toll Free (US/CANADA): +1-855-455-8662

Email: sales@acutemarketreports.com

Website: http://www.acutemarketreports.com